Tag Archives: ADHD

Earning It

“They make money the old fashioned way. They earn it.“–Houseman, J.,    Barney, S.  1979 The news that AbbVie is pulling out of its arranged marriage with Shire Pharmaceuticals (because tax law revisions are changing the value of inversion deals) … Continue reading

Posted in Big Pharma, BioFollies | Tagged , , , | Leave a comment

Alcobra’s Selective Inattention

Last week, in the October issue of NeuroPerspective, which covered ADHD, we noted the delay in Alcobra’s disclosure of Phase III data for MDX (metadoxine), and stated “ our suspicion is that the analysis of the primary and secondary endpoints … Continue reading

Posted in BioFollies, Biotech | Tagged , , , | 1 Comment

Pfizer Catches NextWave

Pfizer has acquired NextWave Pharmaceuticals, whose main asset is the recently approved Quillivant for ADHD, which is a liquid formulation of CR methylphenidate. Pfizer had optioned the company for $20 million a few months ago, another $255 million is payable … Continue reading

Posted in Uncategorized | Tagged , , , , , | Leave a comment

The New York Times Sunday Review Welcomes You to the Pleasuredome

NIR is not particularly prone to media paranoia, the notion that there are hidden, manipulative agendas behind stories and opinion pieces. But we are starting to wonder about the NYT Sunday Review. For the second time in three weeks, they … Continue reading

Posted in Muddled Media | Tagged , , , | Leave a comment

Someone Please Wake Up Andrew Rosenthal

‘Ritalin Gone Wrong’ was the headline on the front page of the New York Times Sunday Review today, a publication which is generally seen as a source of reason, not underinformed pseudoscience. But there it was, Professor Emeritus L. Alan … Continue reading

Posted in Muddled Media, Science | Tagged , , , , | 2 Comments